Ascendis Pharma A/S

Total Valuation

Ascendis Pharma A/S carries a market capitalization of 14.62B, placing it among publicly traded companies globally. Its enterprise value stands at 14.97B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Ascendis Pharma A/S currently has 65.67M shares outstanding.

Valuation Ratios

Ascendis Pharma A/S trades at a trailing price-to-earnings ratio of 19.50. The price-to-sales ratio is 13.81, and the price-to-book ratio stands at 10.67.

Enterprise Valuation

On an enterprise value basis, Ascendis Pharma A/S trades at an EV/EBITDA multiple of 53.40 and an EV/FCF ratio of 11.74. The EV/Sales ratio of 14.30 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 56.98 provides insight into valuation relative to core operating earnings.

Financial Position

Ascendis Pharma A/S maintains a current ratio of 2.99, meaning it holds 3.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 31.33, indicating elevated leverage, while an interest coverage ratio of 2.30 demonstrates limited ability to service its debt obligations.

Financial Efficiency

Taxes

Over the trailing twelve months, Ascendis Pharma A/S has paid -643.92M in income taxes, reflecting an effective tax rate of 10.05.

Stock Price Statistics

Ascendis Pharma A/S's stock has gained approximately 14.21958% over the past 52 weeks. The 50-day moving average sits at 243.64, while the 200-day moving average is 236.59.

Income Statement

Over the trailing twelve months, Ascendis Pharma A/S generated 1.05B in revenue and converted that into 741.76M in net income, yielding earnings per share of 11.65. EBITDA reached 280.35M, while operating income came in at 262.72M.

Balance Sheet

Ascendis Pharma A/S holds 812.26M in cash and equivalents against 450.07M in total debt, resulting in a net debt position of -362.19M. Total book value stands at 1.44B, with working capital of 925.52M providing operational flexibility.

Cash Flow

Ascendis Pharma A/S produced 349.51M in operating cash flow over the past twelve months. After subtracting -3.44M in capital expenditures, free cash flow totaled 346.07M - equivalent to 5.59 per share.

Margins

Ascendis Pharma A/S operates with a gross margin of 91.30, reflecting its pricing power and cost economics. The operating margin of 25.09 and net profit margin of 70.84 provide insight into operational efficiency.

Dividends & Yields

Scores

Ascendis Pharma A/S posts an Altman Z-Score of 11.00, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.